All In Biotech

Drug Trial Radar · NCT07401381

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Quarterly Letrozole SIE and Once Daily 2.5 mg Oral Letrozole (Femara®) in Post-Menopausal Women Treated With Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. (SIE-1)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

May 2028

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.

Conditions

  • Hormone Receptor Positive Early Breast Cancer

Interventions

  • US-sourced oral Femara® + Letrozole SIEDrug

    US-sourced Femara® 2.5 mg/day oral for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)

  • EU sourced oral Femara® + Letrozole SIEDrug

    EU-sourced oral Femara® 2.5 mg/day for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve within a dosing interval at Steady-State (SS AUCtau)Time frame: After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® on Day 14 TP1

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Precision NextGen Oncology and Research Center (Investigational Site number USA-001)

    Beverly Hills, California · Recruiting

  • D&H National Research Centers INC (Investigational Site number USA-002)

    Margate, Florida · Recruiting

  • United Medical Research (Investigational Site number USA-005)

    Port Orange, Florida · Recruiting

  • Investigational Site number SRB-004

    Belgrade, Serbia · Recruiting

  • Investigational Site number SRB-002

    Belgrade, Serbia · Recruiting

  • Investigational Site number SRB-001

    Kamenitz, Serbia · Recruiting

  • Investigational Site number SRB-003

    Kragujevac, Serbia · Recruiting

  • Investigational Site number SRB-005

    Niš, Serbia · Recruiting

  • Hospital Universitario Fundación Alcorcón (Investigational Site number ESP-015)

    Alcorcón, Spain · Recruiting

  • NEXT Oncology. Phase I Unit / IOB - Hospital Quironsalud Barcelona (Investigational Site number ESP-002)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Virgen de las Nieves (Investigational Site number ESP-011)

    Granada, Spain · Recruiting

  • Hospital Universitario de Jaén (HUJ) (Investigational Site number ESP-005)

    Jaén, Spain · Recruiting

  • Complejo Asistencial Universitario de León - Hospital de León (Investigational Site number ESP-013)

    León, Spain · Recruiting

  • Hospital Universitario Arnau de Vilanova de Lleida (Investigational Site number ESP-003)

    Lleida, Spain · Recruiting

  • Hospital Quirónsalud Málaga (Investigational Site number ESP-001)

    Málaga, Spain · Recruiting

  • Althaia Xarxa Assistencial Universitària de Manresa F.P (Investigational Site number ESP-012)

    Manresa, Spain · Recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca (Investigational Site number ESP-009)

    Murcia, Spain · Recruiting

  • NEXT Oncology Phase I Unit - Hospital Universitario Quironsalud Madrid (Investigational Site number ESP-008)

    Pozuelo de Alarcón, Spain · Recruiting

  • Hospital Universitari Sant Joan de Reus (Investigational Site number ESP-004)

    Reus, Spain · Recruiting

  • Consorci Corporació Sanitària Parc Taulí - Hospital de Sabadell (Investigational Site number ESP-006)

    Sabadell, Spain · Recruiting

  • Hospital Clinico Universitario Santiago de Compostela (Investigational Site number ESP-007)

    Santiago de Compostela, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.